ADMA BIOLOGICS, INC. (ADMA) Operating Margin
- Operating margin · 12 months: Value 43.82%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 43.82% | Operating income / revenue. Period ending 2026-06-30. $224.48M ÷ $512.27M × 100 ≈ 43.82% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 224.48M USD | Operating Income (Loss) |
| Revenue | 512.27M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 11.52M USD | Research and Development Expense |
| Selling, general and administration | 98.77M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $224.48M | $512.27M | (m) | $11.52M | $98.77M | 43.82% |
| 2026-03-31 | $214.84M | $509.86M | (m) | $6.53M | $94.24M | 42.14% |
| 2025-12-31 | $191.44M | $510.17M | (m) | $4.76M | $91.58M | 37.53% |
| 2025-09-30 | $167.01M | $488.56M | (m) | $3.78M | $91.39M | 34.19% |
| 2025-06-30 | $155.64M | $474.17M | (m) | $2.66M | $88.17M | 32.82% |
| 2025-03-31 | $152.04M | $459.38M | (m) | $2.19M | $82.56M | 33.10% |
| 2024-12-31 | $138.98M | $426.45M | (m) | $1.81M | $74.12M | 32.59% |
| 2024-09-30 | $114.89M | $382.81M | (m) | $1.87M | $66.34M | 30.01% |
| 2024-06-30 | $83.94M | $330.24M | (m) | $2.05M | $62.51M | 25.42% |
| 2024-03-31 | $44.27M | $283.18M | (m) | $2.90M | $60.15M | 15.63% |
| 2023-12-31 | $21.63M | $258.21M | (m) | $3.30M | $59.02M | 8.38% |
| 2023-09-30 | $1.34M | $234.29M | (m) | $3.93M | $57.38M | 0.57% |
| 2023-06-30 | $-16.66M | $208.11M | (m) | $4.37M | $55.55M | -8.01% |
| 2023-03-31 | $-25.36M | $181.89M | (m) | $3.85M | $53.27M | -13.94% |
| 2022-12-31 | $-39.37M | $154.08M | (m) | $3.61M | $52.46M | -25.55% |
| 2022-09-30 | $-46.50M | $130.48M | (m) | $3.27M | $50.26M | -35.64% |
| 2022-06-30 | $-51.62M | $110.07M | (m) | $3.00M | $48.09M | -46.90% |
| 2022-03-31 | $-58.02M | $94.00M | (m) | $3.28M | $46.56M | -61.73% |
| 2021-12-31 | $-58.37M | $80.94M | (m) | $3.65M | $42.90M | -72.12% |
| 2021-09-30 | $-62.40M | $68.52M | (m) | $3.93M | (m) | -91.08% |
| 2021-06-30 | $-61.77M | $58.11M | (m) | $4.87M | (m) | -106.29% |
| 2021-03-31 | $-63.31M | $48.07M | (m) | $5.37M | (m) | -131.71% |
| 2020-12-31 | $-64.91M | $42.22M | (m) | $5.91M | (m) | -153.75% |
| 2020-09-30 | $-55.52M | $40.30M | (m) | $5.36M | (m) | -137.77% |
| 2020-06-30 | $-50.77M | $37.25M | (m) | $4.14M | (m) | -136.31% |
| 2020-03-31 | $-44.99M | $36.02M | (m) | $3.00M | (m) | -124.89% |
| 2019-12-31 | $-41.42M | $29.35M | (m) | $2.34M | (m) | -141.14% |
| 2019-09-30 | $-50.15M | $21.37M | (m) | $2.80M | (m) | -234.67% |
| 2019-06-30 | $-54.89M | $18.38M | (m) | $3.31M | (m) | -298.68% |
| 2019-03-31 | $-56.96M | $16.47M | (m) | $3.83M | (m) | -345.83% |
| 2018-12-31 | $-60.29M | $16.99M | (m) | $3.93M | (m) | -354.95% |
| 2018-09-30 | $-54.28M | (m) | (m) | $5.94M | (m) | (m) |
| 2018-06-30 | $-54.92M | (m) | (m) | $6.43M | (m) | (m) |
| 2018-03-31 | $-49.91M | (m) | (m) | $6.32M | (m) | (m) |
| 2017-12-31 | $-39.31M | (m) | (m) | $6.23M | (m) | (m) |
| 2017-09-30 | $-32.71M | (m) | (m) | $4.95M | (m) | (m) |
| 2017-06-30 | $-22.02M | (m) | (m) | $4.81M | (m) | (m) |
| 2017-03-31 | $-19.11M | (m) | (m) | $6.85M | (m) | (m) |
| 2016-12-31 | $-17.33M | (m) | (m) | $7.69M | (m) | (m) |
| 2016-09-30 | $-17.52M | (m) | (m) | $9.10M | (m) | (m) |
| 2016-06-30 | $-18.44M | (m) | (m) | $9.54M | (m) | (m) |
| 2016-03-31 | $-16.47M | (m) | (m) | $7.64M | (m) | (m) |
| 2015-12-31 | $-15.51M | (m) | (m) | $7.02M | (m) | (m) |
| 2015-09-30 | $-15.09M | (m) | (m) | $6.94M | (m) | (m) |
| 2015-06-30 | $-13.47M | (m) | (m) | $6.31M | (m) | (m) |
| 2015-03-31 | $-13.54M | (m) | (m) | $6.59M | (m) | (m) |
| 2014-12-31 | $-16.02M | (m) | (m) | $9.52M | (m) | (m) |
| 2014-09-30 | $-16.83M | (m) | (m) | $10.55M | (m) | (m) |
| 2014-06-30 | $-16.32M | (m) | (m) | $10.48M | (m) | (m) |
| 2014-03-31 | $-17.58M | (m) | (m) | $12.17M | (m) | (m) |
| 2013-12-31 | $-15.04M | (m) | (m) | $9.30M | (m) | (m) |
| 2013-09-30 | $-12.76M | $3.17M | (m) | $7.61M | (m) | -403.07% |
| 2013-06-30 | $-13.48M | $2.42M | (m) | $8.15M | (m) | -557.16% |
| 2013-03-31 | $-9.85M | $1.91M | (m) | $4.85M | (m) | -516.39% |
| 2012-12-31 | $-7.91M | $1.12M | (m) | $3.47M | (m) | -707.36% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-4.62M | $761.04K | (m) | $646.76K | (m) | -607.45% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |